Editorial Policy

GLP Loss covers the GLP-1 drugs sold online — semaglutide and tirzepatide, compounded and brand, by injection and by tablet. This is how we decide what goes on a page. It sits alongside our methodology (the scoring rubric), nature of reviews (what can and cannot move a verdict), and our disclosures (how we are paid).

1. Evidence does not transfer from the brand to the compound

This is the rule that does the most work on this site, because the whole category is built on blurring it. The trials behind these drugs — STEP 1, SURMOUNT-1, SELECT — studied the approved products at the approved doses. A compounded preparation contains the same molecule by intent, but it was not in those trials, it is not FDA-approved, and the FDA does not review it for safety, efficacy or quality before it ships. A seller quoting a 15% or 20% weight-loss figure beside a compounded vial is citing a trial its own product was not in.

So we say which product a number came from, every time. The same applies to dose: a “microdose” protocol is not the schedule any published trial used, and a result measured at 2.4 mg weekly is not evidence for a fraction of it. Where a claim has no trial behind it at all we say there is none, and we say what we searched to establish that — an absence claim is worth nothing without the census behind it.

2. Primary sources, and no marketing language

Every factual claim traces to the trial publication, the FDA or DailyMed label, or the paper of record. Press releases, program descriptions, affiliate one-sheets and AI-generated summaries are not evidence. We report effect sizes, intervals and durations rather than adjectives.

We also do not repeat a seller’s claims in our own voice. “Clinically proven”, “scientifically proven” and “the fountain of youth peptide” are phrases we have read on real GLP-1 product pages this year. When we quote one it is in quotation marks and attributed, because it is a fact about the seller, not about the molecule.

3. Citations are verified live, never from memory

Before publication every reference is checked against the source of record — PubMed, DailyMed, ClinicalTrials.gov or the journal — to confirm the authors, the year, the journal and the specific figure being cited. A citation that cannot be located and confirmed does not publish, and a plausible-looking reference written from memory is treated as a fabrication rather than a shortcut.

4. Prices are read off the seller’s page, and dated

Not from a program description, not from an affiliate feed. Those routinely disagree with the live page, and in a cash-pay compounded market the live page is the only thing a reader can actually buy from. Each price carries the month it was read, because it will change and you should be able to tell how old ours is.

Where a seller does not publish a milligram dose — which is most of them — we report that as a finding rather than quietly comparing prices as if it did not matter. A monthly rate is not a value judgment until you know what you get for it.

5. Bylines and what we do not claim

We do not attach credentials, degrees or institutional affiliations to our writers, so the work is judged on its sourcing rather than on a title. A stable byline means a stable beat — the same name always covers the same ground, so you always know whose reasoning to argue with. The masthead is on our writers page.

6. No clinician on staff, and we will not imply otherwise

GLP Loss does not have a licensed clinician as a named medical reviewer. We do not claim individualized clinical review and we do not present any of this as care guidance. Our standard is primary-source verification, disclosed rather than dressed up — which is also why a medical disclaimer appears on our health content. Saying so costs us something in perceived authority; claiming a reviewer we do not have would cost you more.

7. AI assistance

Where drafting tools including AI are used, the output is a draft and nothing more. Every claim is then verified by a human against the primary literature by the process above. Editorial responsibility for accuracy rests entirely with us, and an AI summary is never a source of fact.

8. Corrections

We fix errors in public and date the change. If you find a misread figure, a stale price or a broken source link, see our corrections policy or write to corrections@glploss.com.